Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.49 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687505 | 0.85 | NR1H2 (0.52) | NR1H2NR1H3RORCKCNH2LOXL2 | |
| SCHEMBL5893286 | 0.83 | NR1H2 (0.51) | NR1H2NR1H3RORCKCNH2LOXL2 | |
| SCHEMBL5399297 | 0.83 | PTGES2 (0.53) | NR1H2NR1H3KCNH2CTSC | |
| SCHEMBL5893176 | 0.83 | NR1H2 (0.51) | NR1H2NR1H3RORCKCNH2LOXL2 | |
| SCHEMBL6243674 | 0.82 | KCNH2 (0.50) | NR1H2NR1H3KCNH2LOXL2 | |
| SCHEMBL30661269 | 0.80 | DRD2 (0.48) | NR1H2NR1H3LOXL2 | |
| SCHEMBL710198 | 0.80 | DRD2 (0.48) | NR1H2NR1H3LOXL2 | |
| SCHEMBL2140712 | 0.80 | PTGS2 (0.53) | NR1H2NR1H3KCNH2RXRALOXL2 | |
| SCHEMBL258355 | 0.78 | TAAR1 (0.52) | — | |
| SCHEMBL21753374 | 0.78 | PIK3CG (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039027-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | NR1H2 3629/4885NR1H3 3858/4885RORC 4048/4885 |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | PREP, GAA, DNPEP | NR1H2 3539/4885NR1H3 3817/4885RORC 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.